396 related articles for article (PubMed ID: 35063123)
1. Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose.
Kuhlmann C; Mayer CK; Claassen M; Maponga T; Burgers WA; Keeton R; Riou C; Sutherland AD; Suliman T; Shaw ML; Preiser W
Lancet; 2022 Feb; 399(10325):625-626. PubMed ID: 35063123
[No Abstract] [Full Text] [Related]
2. Follow-Up and Comparative Assessment of SARS-CoV-2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA-1273 Heterologous Booster Vaccination.
Younes S; Nicolai E; Pieri M; Bernardini S; Daas HI; Al-Sadeq DW; Younes N; Shurrab FM; Nizamuddin PB; Humaira F; Al-Dewik N; Yassine HM; Abu-Raddad LJ; Ismail A; Nasrallah GK
Influenza Other Respir Viruses; 2024 May; 18(5):e13290. PubMed ID: 38706402
[TBL] [Abstract][Full Text] [Related]
3. Follow-up SARS-CoV-2 serological study of a health care worker cohort following COVID-19 booster vaccination.
Hönning A; Tomczyk S; Hermes J; Grossegesse M; Hofmann N; Michel J; Neumann M; Nitsche A; Hoppe B; Eckmanns T; Schmidt-Traub H; Zappel K
BMC Infect Dis; 2024 Apr; 24(1):436. PubMed ID: 38658874
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study.
Fabiani M; Puopolo M; Morciano C; Spuri M; Spila Alegiani S; Filia A; D'Ancona F; Del Manso M; Riccardo F; Tallon M; Proietti V; Sacco C; Massari M; Da Cas R; Mateo-Urdiales A; Siddu A; Battilomo S; Bella A; Palamara AT; Popoli P; Brusaferro S; Rezza G; Menniti Ippolito F; Pezzotti P;
BMJ; 2022 Feb; 376():e069052. PubMed ID: 35144968
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
Stuart ASV; Shaw RH; Liu X; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Darton T; Dinesh T; Duncan CJA; England A; Faust SN; Ferreira DM; Finn A; Goodman AL; Green CA; Hallis B; Heath PT; Hill H; Horsington BM; Lambe T; Lazarus R; Libri V; Lillie PJ; Mujadidi YF; Payne R; Plested EL; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Screaton GR; Singh N; Turner DPJ; Turner PJ; Vichos I; White R; Nguyen-Van-Tam JS; Snape MD;
Lancet; 2022 Jan; 399(10319):36-49. PubMed ID: 34883053
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of Two Doses of BNT162b2 mRNA COVID-19 Vaccine with a ChAdOx1-S Booster Dose among Navy Personnel in Mexico.
Ventura-Enríquez Y; Cortina-De la Rosa E; Díaz-Padilla E; Murrieta S; Segundo-Martínez S; Fernández-Sánchez V; Vargas-De-León C
Viruses; 2024 Apr; 16(4):. PubMed ID: 38675894
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario.
Nasreen S; Chung H; He S; Brown KA; Gubbay JB; Buchan SA; Fell DB; Austin PC; Schwartz KL; Sundaram ME; Calzavara A; Chen B; Tadrous M; Wilson K; Wilson SE; Kwong JC;
Nat Microbiol; 2022 Mar; 7(3):379-385. PubMed ID: 35132198
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 Vaccine Combination Was Superior in Real-world Study.
Abbasi J
JAMA; 2021 Dec; 326(22):2250. PubMed ID: 34905046
[No Abstract] [Full Text] [Related]
9. COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer.
Zeng C; Evans JP; Chakravarthy K; Qu P; Reisinger S; Song NJ; Rubinstein MP; Shields PG; Li Z; Liu SL
Cancer Cell; 2022 Feb; 40(2):117-119. PubMed ID: 34986328
[No Abstract] [Full Text] [Related]
10. Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.
Goodyear CS; Patel A; Barnes E; Willicombe M; Siebert S; de Silva TI; Snowden JA; Lim SH; Bowden SJ; Billingham L; Richter A; Carroll M; Carr EJ; Beale R; Rea D; Parry H; Pirrie S; Lim Z; Satsangi J; Dunachie SJ; Cook G; Miller P; Basu N; Gilmour A; Hodgkins AM; Evans L; Hughes A; Longet S; Meacham G; Yong KL; A'Hearne MJ; Koh MBC; Burns SO; Orchard K; Paterson C; McIlroy G; Murray SM; Thomson T; Dimitriadis S; Goulston L; Miller S; Keillor V; Prendecki M; Thomas D; Kirkham A; McInnes IB; Kearns P;
Lancet Rheumatol; 2024 Jun; 6(6):e339-e351. PubMed ID: 38734019
[TBL] [Abstract][Full Text] [Related]
11. Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination.
Kaku CI; Champney ER; Normark J; Garcia M; Johnson CE; Ahlm C; Christ W; Sakharkar M; Ackerman ME; Klingström J; Forsell MNE; Walker LM
Science; 2022 Mar; 375(6584):1041-1047. PubMed ID: 35143256
[TBL] [Abstract][Full Text] [Related]
12. Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2.
Markewitz R; Juhl D; Pauli D; Görg S; Junker R; Rupp J; Engel S; Steinhagen K; Herbst V; Zapf D; Krüger C; Brockmann C; Leypoldt F; Dargvainiene J; Schomburg B; Sharifzadeh S; Nejad LS; Wandinger KP; Ziemann M
Front Immunol; 2022; 13():811020. PubMed ID: 35126395
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the neutralizing antibody response in Omicron breakthrough cases in healthcare workers who received the homologous booster of Moderna mRNA-1273.
Gillot C; Tré-Hardy M; Cupaiolo R; Blairon L; Wilmet A; Beukinga I; Dogné JM; Douxfils J; Favresse J
Virology; 2024 Jul; 595():110082. PubMed ID: 38636363
[TBL] [Abstract][Full Text] [Related]
14. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden.
Nordström P; Ballin M; Nordström A
Lancet; 2022 Feb; 399(10327):814-823. PubMed ID: 35131043
[TBL] [Abstract][Full Text] [Related]
15. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of a bivalent BA.1 COVID-19 booster vaccine in people with HIV in the Netherlands.
Jongkees MJ; Tan NH; Geers D; de Vries RD; GeurtsvanKessel CH; Hensley KS; Sablerolles RSG; Bogers S; Gommers L; Blakaj B; Miranda Afonso P; Hansen BE; Rijnders BJA; Brinkman K; van der Kuy PHM; Roukens AHE; Rokx C
AIDS; 2024 Jul; 38(9):1355-1365. PubMed ID: 38788210
[TBL] [Abstract][Full Text] [Related]
17. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination.
Pozzetto B; Legros V; Djebali S; Barateau V; Guibert N; Villard M; Peyrot L; Allatif O; Fassier JB; Massardier-Pilonchéry A; Brengel-Pesce K; Yaugel-Novoa M; Denolly S; Boson B; Bourlet T; Bal A; Valette M; Andrieu T; Lina B; ; Cosset FL; Paul S; Defrance T; Marvel J; Walzer T; Trouillet-Assant S
Nature; 2021 Dec; 600(7890):701-706. PubMed ID: 34673755
[TBL] [Abstract][Full Text] [Related]
19. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.
Planas D; Saunders N; Maes P; Guivel-Benhassine F; Planchais C; Buchrieser J; Bolland WH; Porrot F; Staropoli I; Lemoine F; Péré H; Veyer D; Puech J; Rodary J; Baele G; Dellicour S; Raymenants J; Gorissen S; Geenen C; Vanmechelen B; Wawina-Bokalanga T; Martí-Carreras J; Cuypers L; Sève A; Hocqueloux L; Prazuck T; Rey FA; Simon-Loriere E; Bruel T; Mouquet H; André E; Schwartz O
Nature; 2022 Feb; 602(7898):671-675. PubMed ID: 35016199
[TBL] [Abstract][Full Text] [Related]
20. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.
Shaw RH; Stuart A; Greenland M; Liu X; Nguyen Van-Tam JS; Snape MD;
Lancet; 2021 May; 397(10289):2043-2046. PubMed ID: 33991480
[No Abstract] [Full Text] [Related]
[Next] [New Search]
